secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001185185-22-000608
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC subsidiary licenses NMI compounds from JNCASR for Alzheimer's treatment
---------------------------------------------------------------------------

- Hamsa Biopharma (IGC subsidiary) obtains exclusive worldwide license for NMI Compounds from JNCASR.
- NMI Compounds are small molecule inhibitors that may reduce amyloid neurotoxicity, targeting Alzheimer's and other CNS disorders.
- License fee of INR [***] with milestone payment upon FDA Phase II approval; royalties of [***]% of Net Revenue.
- IGC gains rights to prosecute patents, use all licensor technology, and first refusal on future CNS inventions.
- Agreement includes sublicensing rights and term until last patent expiration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000608/0001185185-22-000608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000608/indiaglob20220512_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-22-000608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer